Crucial Update for Long-Term Shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT), DoubleVerify Holdings, Inc. (NYSE: DV), LuxUrban Hotels Inc. (OTC: LUXH), and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office is Looking into Claims for You
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 12 2025
0mins
Source: Globenewswire
Applied Therapeutics Class Action Settlement: A securities fraud class action against Applied Therapeutics has reached a settlement, allowing shareholders who purchased shares before January 3, 2024, to seek corporate reforms and a court-approved incentive award at no cost.
DoubleVerify Holdings Investigation: Grabar Law Office is investigating potential breaches of fiduciary duties by officers of DoubleVerify Holdings, with allegations of misleading statements regarding the company's ad spending and technological capabilities affecting shareholder rights.
LuxUrban Hotels Class Action Update: A securities fraud class action against LuxUrban Hotels has survived a motion to dismiss, with allegations of false statements about hotel leases and financial misrepresentations, allowing shareholders who purchased shares before November 8, 2023, to seek corporate reforms.
Unicycive Therapeutics Investigation: Grabar Law Office is investigating Unicycive Therapeutics for potential securities fraud, with claims that the company overstated its compliance with FDA manufacturing requirements, impacting shareholders who purchased shares before March 29, 2024.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UNCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UNCY
Wall Street analysts forecast UNCY stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.210
Low
21.00
Averages
35.80
High
60.00
Current: 8.210
Low
21.00
Averages
35.80
High
60.00
About UNCY
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Unicyive Therapeutics Faces FDA Decision Amid Stock Volatility
- Impending FDA Decision: Unicyive Therapeutics is awaiting FDA approval for its lead drug, oxylanthanum carbonate, aimed at treating hyperphosphatemia in chronic kidney disease patients, with a potential launch in Q3 2025 if approved, which would significantly enhance the company's market position.
- Significant Stock Volatility: Ahead of the FDA decision, Unicyive's shares fell over 16% on Friday, and if losses persist, it could mark the worst performance since late June 2025, reflecting investor anxiety regarding the approval outcome.
- Analyst Optimism: H.C. Wainwright maintains a Buy rating with a $22 price target, and all ten analysts covering UNCY rate it as ‘Buy’ or higher, indicating a potential upside of about 400% over the next 12 months, showcasing strong market confidence in the drug's prospects.
- Retail Investor Sentiment: According to Stocktwits, retail sentiment around UNCY has remained in the ‘extremely bullish’ territory over the past 24 hours, with message volume increasing by 219%, indicating strong investor interest and anticipation for the FDA decision.
See More
Unicycive's OLC Drug Set for FDA Approval Amid Market Competition
- Drug Development Progress: Unicycive Therapeutics' next-generation phosphate binder, oxylanthanum carbonate (OLC), is set for FDA PDUFA on June 29, aiming to attract patients with unmet medical needs, particularly among chronic kidney disease patients on dialysis.
- Market Competition Analysis: While competitors like Sanofi's Renvela and Ardelyx's Xphosah exist, OLC's smaller tablet size and non-chewable formulation provide a significant advantage in patient compliance, especially given Renvela's requirement for thrice-daily dosing.
- Sales Strategy Planning: Unicycive plans to launch OLC in Q3 and will establish a sales force of approximately 60, focusing on around 2,100 physicians who prescribe hyperphosphatemia drugs, particularly targeting practices near dialysis centers to enhance market penetration.
- Payment System Impact: OLC will be covered under the TDAPA system at 100% of the average sale price for new therapies, followed by a three-year add-on payment at 65%, transitioning to standard ESRD bundled payments after five years, ensuring market stability and sustainability.
See More
Trump's Policy Impact on Biopharma Innovation
- Global Collaboration Necessity: Acadia Pharmaceuticals CEO Catherine Owen Adams emphasized at the FTUS Pharma and Biotech Summit that while Trump's 'Most Favored Nation' policy incentivizes drugmakers to operate more in the US, global partnerships are critical for advancing R&D, highlighting the potential of scientific institutions worldwide.
- China's R&D Advantage: Unicycive Therapeutics CEO Shalabh Gupta noted that his company has established partnerships with researchers in China and South Korea, reflecting a belief that patient needs are global, and pointing to China's cost and efficiency advantages in R&D that may pose long-term competitive pressures on the US.
- US Innovation Outlook: Eric Tokat from Centerview Partners remarked that while Chinese biopharma companies were previously seen as copycats, real innovations are emerging today, stressing that the US must continue funding universities and the NIH to maintain its leadership in biopharma R&D.
- Future Treatment Prospects: Adams predicts that the first drug entirely created by AI will enter testing within the next five years, while Gupta anticipates the development of more 'one and done' therapies, indicating rapid advancements in the biopharma sector.
See More
Unicycive Therapeutics Reports Q1 Loss, Misses EPS Estimates
- Disappointing Earnings: Unicycive Therapeutics reported a Q1 GAAP EPS of -$0.54, missing estimates by $0.08, indicating challenges in profitability that may affect investor confidence.
- Cash Reserves: As of May 11, 2026, the company's unaudited cash, cash equivalents, and marketable securities totaled $57.1 million, suggesting a degree of financial flexibility to support operations in the short term.
- Sufficient Funding: The company believes it has enough resources to fund planned operations into 2027, indicating strategic planning despite current financial setbacks, which may reassure stakeholders about its operational continuity.
- Increased Market Attention: Unicycive Therapeutics presented at the 25th Annual Needham Virtual Healthcare Conference, potentially attracting more investor interest in its future developments and market opportunities.
See More
Kuehn Law Investigates Unicycive Executives for Fiduciary Breaches
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. breached their fiduciary duties to shareholders, with allegations in a federal securities lawsuit claiming the company overstated its readiness to meet FDA manufacturing compliance requirements.
- False Statement Allegations: The lawsuit asserts that insiders at Unicycive failed to disclose that their ability to satisfy FDA requirements was overstated, resulting in public statements being materially false and misleading at all relevant times.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased UNCY stock prior to March 29, 2024, to contact the firm promptly to enforce their rights, emphasizing that shareholder voices are crucial for the integrity and fairness of financial markets.
- Legal Cost Commitment: Kuehn Law commits to covering all case costs without charging investor clients, highlighting its dedication to protecting shareholder rights and encouraging active participation to secure the future of their investments.
See More
Kuehn Law Investigates Unicycive Executives for Fiduciary Breaches
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. breached their fiduciary duties to shareholders, with allegations in a federal securities lawsuit claiming the company overstated its readiness to meet FDA manufacturing compliance requirements.
- False Statement Allegations: The lawsuit asserts that Unicycive exaggerated the regulatory prospects of the OLC NDA, resulting in public statements that were materially false and misleading at all relevant times.
- Shareholder Rights Protection: Kuehn Law urges shareholders who own UNCY stock purchased before March 29, 2024, to contact the firm promptly to enforce their rights, indicating that there may be limited time for legal action.
- Legal Service Commitment: Kuehn Law promises to cover all case costs without charging investor clients, emphasizing the importance of shareholder participation in maintaining the integrity and fairness of financial markets.
See More
Unicyive Therapeutics Faces FDA Decision Amid Stock Volatility
- Impending FDA Decision: Unicyive Therapeutics is awaiting FDA approval for its lead drug, oxylanthanum carbonate, aimed at treating hyperphosphatemia in chronic kidney disease patients, with a potential launch in Q3 2025 if approved, which would significantly enhance the company's market position.
- Significant Stock Volatility: Ahead of the FDA decision, Unicyive's shares fell over 16% on Friday, and if losses persist, it could mark the worst performance since late June 2025, reflecting investor anxiety regarding the approval outcome.
- Analyst Optimism: H.C. Wainwright maintains a Buy rating with a $22 price target, and all ten analysts covering UNCY rate it as ‘Buy’ or higher, indicating a potential upside of about 400% over the next 12 months, showcasing strong market confidence in the drug's prospects.
- Retail Investor Sentiment: According to Stocktwits, retail sentiment around UNCY has remained in the ‘extremely bullish’ territory over the past 24 hours, with message volume increasing by 219%, indicating strong investor interest and anticipation for the FDA decision.
See More
Unicycive's OLC Drug Set for FDA Approval Amid Market Competition
- Drug Development Progress: Unicycive Therapeutics' next-generation phosphate binder, oxylanthanum carbonate (OLC), is set for FDA PDUFA on June 29, aiming to attract patients with unmet medical needs, particularly among chronic kidney disease patients on dialysis.
- Market Competition Analysis: While competitors like Sanofi's Renvela and Ardelyx's Xphosah exist, OLC's smaller tablet size and non-chewable formulation provide a significant advantage in patient compliance, especially given Renvela's requirement for thrice-daily dosing.
- Sales Strategy Planning: Unicycive plans to launch OLC in Q3 and will establish a sales force of approximately 60, focusing on around 2,100 physicians who prescribe hyperphosphatemia drugs, particularly targeting practices near dialysis centers to enhance market penetration.
- Payment System Impact: OLC will be covered under the TDAPA system at 100% of the average sale price for new therapies, followed by a three-year add-on payment at 65%, transitioning to standard ESRD bundled payments after five years, ensuring market stability and sustainability.
See More
Trump's Policy Impact on Biopharma Innovation
- Global Collaboration Necessity: Acadia Pharmaceuticals CEO Catherine Owen Adams emphasized at the FTUS Pharma and Biotech Summit that while Trump's 'Most Favored Nation' policy incentivizes drugmakers to operate more in the US, global partnerships are critical for advancing R&D, highlighting the potential of scientific institutions worldwide.
- China's R&D Advantage: Unicycive Therapeutics CEO Shalabh Gupta noted that his company has established partnerships with researchers in China and South Korea, reflecting a belief that patient needs are global, and pointing to China's cost and efficiency advantages in R&D that may pose long-term competitive pressures on the US.
- US Innovation Outlook: Eric Tokat from Centerview Partners remarked that while Chinese biopharma companies were previously seen as copycats, real innovations are emerging today, stressing that the US must continue funding universities and the NIH to maintain its leadership in biopharma R&D.
- Future Treatment Prospects: Adams predicts that the first drug entirely created by AI will enter testing within the next five years, while Gupta anticipates the development of more 'one and done' therapies, indicating rapid advancements in the biopharma sector.
See More
Unicycive Therapeutics Reports Q1 Loss, Misses EPS Estimates
- Disappointing Earnings: Unicycive Therapeutics reported a Q1 GAAP EPS of -$0.54, missing estimates by $0.08, indicating challenges in profitability that may affect investor confidence.
- Cash Reserves: As of May 11, 2026, the company's unaudited cash, cash equivalents, and marketable securities totaled $57.1 million, suggesting a degree of financial flexibility to support operations in the short term.
- Sufficient Funding: The company believes it has enough resources to fund planned operations into 2027, indicating strategic planning despite current financial setbacks, which may reassure stakeholders about its operational continuity.
- Increased Market Attention: Unicycive Therapeutics presented at the 25th Annual Needham Virtual Healthcare Conference, potentially attracting more investor interest in its future developments and market opportunities.
See More
Kuehn Law Investigates Unicycive Executives for Fiduciary Breaches
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. breached their fiduciary duties to shareholders, with allegations in a federal securities lawsuit claiming the company overstated its readiness to meet FDA manufacturing compliance requirements.
- False Statement Allegations: The lawsuit asserts that insiders at Unicycive failed to disclose that their ability to satisfy FDA requirements was overstated, resulting in public statements being materially false and misleading at all relevant times.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased UNCY stock prior to March 29, 2024, to contact the firm promptly to enforce their rights, emphasizing that shareholder voices are crucial for the integrity and fairness of financial markets.
- Legal Cost Commitment: Kuehn Law commits to covering all case costs without charging investor clients, highlighting its dedication to protecting shareholder rights and encouraging active participation to secure the future of their investments.
See More
Kuehn Law Investigates Unicycive Executives for Fiduciary Breaches
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. breached their fiduciary duties to shareholders, with allegations in a federal securities lawsuit claiming the company overstated its readiness to meet FDA manufacturing compliance requirements.
- False Statement Allegations: The lawsuit asserts that Unicycive exaggerated the regulatory prospects of the OLC NDA, resulting in public statements that were materially false and misleading at all relevant times.
- Shareholder Rights Protection: Kuehn Law urges shareholders who own UNCY stock purchased before March 29, 2024, to contact the firm promptly to enforce their rights, indicating that there may be limited time for legal action.
- Legal Service Commitment: Kuehn Law promises to cover all case costs without charging investor clients, emphasizing the importance of shareholder participation in maintaining the integrity and fairness of financial markets.
See More
